Name: 글로벌 시장 동향
SKU: CD1347
Availability: InStock

보고서 요약(국문)

시장 개요
전 세계 혈액종양학 검사 시장은 2022년 2억 8천만 달러 규모에 도달했으며, 2030년까지 6억 2천만 달러 규모로 성장할 것으로 예상됩니다. 예측 기간(2023~2030년) 동안 연평균 성장률(CAGR)은 4.8%입니다.
혈액종양학은 혈액학(혈액 연구)과 종양학(암 연구)이라는 두 가지 의학 분야를 통합한 분야입니다. 혈액종양 전문의는 혈액암 및 혈액 관련 질환의 진단, 치료 및 예방을 전문으로 합니다. 혈액종양학 분야는 혈액암 및 관련 암의 치료를 다룹니다.
시장 동향
약물 진단 및 서비스 분야의 기술 발전
기술 발전과 새로운 첨단 제품 출시가 전 세계 혈액종양학 검사 시장의 성장을 촉진하고 있습니다. 예를 들어, 2022년 8월 Thermo Fisher Scientific은 정밀 종양학 바이오마커 검사에 대한 접근성을 확대하기 위해 CE-IVD(IVDD) 차세대 염기서열 분석 검사 및 분석 소프트웨어를 출시했습니다. 마찬가지로, 2022년 6월 Burning Rock Biotech Limited는 OverC 다중 암 예측 혈액 검사에 대해 CE 마크를 획득했습니다. OverC 다중 암 예측 혈액 검사는 정성적 차세대 염기서열 분석(NGS) 기반 체외 진단 기기입니다. 또한, 2021년 11월 SAN DIEGO와 Genetic Alliance는 유전 질환으로 고통받는 전 세계 수만 명의 사람들에게 전장 유전체 염기서열 분석(WGS) 접근성을 제공하는 것을 목표로 하는 iHope Genetic Health 프로그램을 만들었습니다.
맞춤형 의학에 대한 인식이 높아짐에 따라 시장은 수익성 있는 성장 기회를 얻고 있습니다.
맞춤형 의학은 개인의 유전적 프로필을 활용하여 질병의 예방, 진단 및 치료를 위한 결정을 내리는 의학 분야입니다. 환자의 유전적 프로필에 대한 지식은 의사가 가장 적합한 약물이나 치료법을 선택하고 적절한 용량이나 투여 방식을 적용하는 데 도움이 될 수 있습니다. 개인 맞춤형 의학에 대한 인식이 높아지고 이를 구현하려는 노력이 증가함에 따라 시장에 매우 수익성 높은 성장 기회가 제공되고 있습니다. 예를 들어, 2021년 1월 FDA는 개인 맞춤형 의학의 역할이 확대됨에 따라 의사들에게 새로운 치료법 설계에 대한 지식을 제공하는 데 참여한다고 발표했습니다. 또한 유럽 암 환자 연합(ECPC)은 11월 한 달 동안 '개인 맞춤형 의학 인식의 달: 암의 비밀을 밝히다'라는 캠페인을 통해 암 분자 검사에 대한 접근성의 중요성을 강조하며 최초의 개인 맞춤형 의학 인식의 달 행사를 주도했습니다.
세그먼트 분석
글로벌 혈액종양학 검사 시장은 제품 및 서비스, 암 유형, 기술 및 지역별로 세분화됩니다.
새로운 기술 발전, 제품 출시 및 최근 개발로 인해
협력 및 제품 출시와 같은 시장 개발이 증가함에 따라 예측 기간 동안 서비스 부문의 성장이 촉진될 것으로 예상됩니다. 예를 들어, 2020년 8월 Thermo Fisher Scientific은 Ion Torrent Genexus 시스템용 혈액종양학 검사 키트를 출시했습니다. 또한, 2022년 5월 카타르 게놈 프로그램(QGP)의 카타르 재단(QF) 부문과 Thermo Fisher Scientific은 카타르에서 유전체 연구 및 예측 유전체학의 임상 적용을 발전시키기 위한 파트너십을 체결하여 전 세계 아랍 인구에 정밀 의학의 혜택을 확대하는 데 기여했습니다. 마찬가지로, 2022년 8월 마운트 시나이 의료 시스템과 아이칸 의과대학은 리제네론 유전학 센터(RGC)와 함께 마운트 시나이 밀리언 헬스 디스커버리 프로그램이라는 새로운 인간 게놈 시퀀싱 연구 프로젝트를 시작했습니다. 따라서 앞서 언급한 데이터는 예측 기간 동안 서비스 부문이 전 세계 혈액종양학 검사 시장을 주도할 것임을 시사합니다.
지리적 시장 침투
주요 업체들의 강력한 입지와 친환경 제품 사용에 대한 인식 제고
북미는 백혈병 발병 사례 증가, 우수한 의료비 상환 정책, 그리고 이 지역 시장의 대부분을 점유하고 있는 주요 업체들의 존재로 인해 예측 기간 동안 전 세계 혈액종양학 검사 시장을 주도할 것으로 예상됩니다. 예를 들어, 캐나다 암 협회 보고서에 따르면 2021년 캐나다에서 백혈병 진단을 받은 사람은 6,700명이 넘었으며, 그중 약 4,000명이 남성이고 약 2,700명이 여성이었습니다. 또한, 미국 암 협회는 2022년 미국에서 약 60,650건의 백혈병 신규 사례와 20,050건의 급성 골수성 백혈병(AML) 신규 사례가 진단되었다고 기록했습니다. 급성 골수성 백혈병(AML)은 전체 암의 약 1%를 차지합니다. 또한, Abbott Laboratories, Thermo Fisher Scientific, Illumina는 북미 지역에서 시장 점유율의 대부분을 차지하는 주요 시장 참여업체로서, 이 지역이 세계 시장에서 주도적인 역할을 하고 있음을 보여줍니다.
경쟁 환경
주요 글로벌 기업으로는 F. Hoffman-La Roche Ltd., Abbott Laboratories, Qiagen N.V., Thermo Fisher Scientific, Inc., Illumina, Inc., Bio-Rad Laboratories, Inc., ICON PLC, Archerdx, Inc., Invivoscribe, Inc., Adaptive Biotechnologies 등이 있습니다.

COVID-19 영향 분석
제품 및 서비스 유형별
• 기기
• 시약 및 소모품
• 서비스
기술별
• PCR(중합효소 연쇄 반응)
• IHC(면역조직화학)
• NGS(차세대 염기서열 분석)
• 세포유전학
• 기타
암 유형별
• 백혈병
o 급성 골수성 백혈병
o 급성 림프구성 백혈병
o 기타
• 림프종
• 다발성 골수종
• 기타
최종 사용자별
• 임상 검사실
• 병원
• 학술 및 연구 기관
• 기타
지역별
• 북미
o 미국
o 캐나다
o 멕시코
• 유럽
o 독일
o 영국
o 프랑스
o 이탈리아
o 러시아
o 기타 유럽
• 남미
o 브라질
o 아르헨티나
o 기타 남미
• 아시아 태평양
o 중국
o 인도
o 일본
o 호주
o 기타 아시아 태평양
• 중동 및 아프리카
주요 동향
• 2022년, 미국 FDA는 스위스 F. Hoffmann-La Roche의 cobras EZH2 유전자 변이 검사를 여포성 림프종 환자를 위한 동반 진단 검사로 승인했습니다.

• 2020년, F. Hoffmann-La Roche와 미국 Illumina는 종양학 분야에서 NGS 기반 검사의 도입을 확대하기 위해 15년간의 비독점 협력 계약을 체결했습니다.

• 2021년, 독일 QIAGEN과 미국 Denovo Biopharma는 가장 대표적인 림프계 암 중 하나인 미만성 거대 B세포 림프종(DLBCL) 치료를 위한 혈액 기반 동반 진단(CDx) 검사를 개발하기 위한 파트너십을 체결했습니다.
보고서 구매 이유

• 제품, 적용 분야 및 지역별 글로벌 혈액종양 검사 시장 세분화를 시각화하고 주요 상업 자산 및 주요 업체를 파악합니다.

• 트렌드 분석 및 공동 개발을 통해 사업 기회를 발굴합니다.

• 모든 세그먼트를 포함한 혈액종양 검사 시장 수준의 다양한 데이터가 담긴 엑셀 자료를 제공합니다.

• 심층적인 질적 인터뷰와 연구를 바탕으로 종합적인 분석 결과를 담은 PDF 보고서를 제공합니다.

• 주요 업체들의 핵심 제품을 포함한 제품 맵핑 자료를 엑셀 파일로 제공합니다.

글로벌 혈액종양 검사 시장 보고서는 약 69개의 표, 71개의 그림, 195페이지 분량입니다.
주요 고객 (2023년 기준)
• 제조업체/구매자
• 산업 투자자/투자은행
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Market Overview
The global hemato oncology Testing market reached US$ 280 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 620 million by 2030. The market is growing at a CAGR of 4.8% during the forecast period (2023-2030).
Hematologic oncology integrates two fields of medicine: hematology, the study of the blood, and oncology, the study of cancer. Hematologic oncologists are trained in diagnosing, treating, and preventing blood cancers and blood-related disorders. The field of haemato-oncology deals with the treatment of blood and related cancers.
Market Dynamics
Technological advancements in drug diagnosis and services
The growing advancements and new technologically advanced product introductions into the market are boosting the global hemato oncology testing market growth. For instance, in August 2022, Thermo Fisher Scientific introduced CE-IVD (IVDD) next-generation sequencing test and analysis software to extend access to precision oncology biomarker testing. Likewise, in June 2022, Burning Rock Biotech Limited was granted a CE marking for its OverC multi-cancer estimation blood test. OverC Multi-Cancer Detection Blood Test is a qualitative next-generation sequencing (NGS)-based in vitro diagnostic device. Similarly, in November 2021, SAN DIEGO and Genetic Alliance created the iHope Genetic Health program targeted at delivering whole-genome sequencing access (WGS) to tens of thousands of individuals all over the globe affected by genetic disease.
Growing awareness regarding personalized medicines is presenting the market with lucrative growth opportunities.
Personalized medicine is a blossoming practice of medicine that employs an individual's genetic profile to direct decisions formed for the prevention, diagnosis, and treatment of the disorder. Knowledge of a patient's genetic profile can aid physicians to choose the most accurate medication or therapy and administer it utilizing the appropriate dose or regimen. The growing awareness and efforts to implement personalized medicine are providing the market with very lucrative growth opportunities For instance, in January 2021, the FDA declared its involvement in providing physicians with knowledge on the designing of novel therapies as the role of personalized medicine keeps on expanding. Furthermore, the European Cancer Patient Coalition (ECPC) lead the first Personalized Medicine Awareness Month throughout November, the ECPC promoted the significance of access to cancer molecular testing during a month-long advocacy campaign called, Personalized Medicine Awareness Month: Cracking the Cancer Code.
Segment Analysis
The global hemato oncology testing market is segmented based on Product & Services, Cancer Type, Technology, and region.
Owing to growing new technological advancements, product launches, and recent development
The increasing market developments such as collaborations, and product launches among others are boosting the services segment growth during the forecast period. For instance, in August 2020 Thermo Fisher Scientific introduced hematology-oncology assays for the Ion Torrent Genexus System. Also, in May 2022, the Qatar Foundation (QF) division of the Qatar Genome Program (QGP), and Thermo Fisher Scientific partnered for the advancement of genomic research and clinical applications of predictive genomics in Qatar as a step in the direction of expanding the benefits of precision medicine all over the Arab populations worldwide. Similarly, in August 2022, Mount Sinai Health System and the Icahn School of Medicine introduced a new human genome sequencing research project known as the Mount Sinai Million Health Discoveries Program with the Regeneron Genetics Center (RGC). Thus, the mentioned data indicates that the services segment will dominate the global hemato-oncology testing market throughout the forecast period.
Geographical Penetration
The strong presence of major players and increased awareness about the use of eco-friendly products
North America dominates the global hemato oncology testing market during the forecast period, owing to the growing cases of leukemia, better reimbursement policies, and the presence of key market players holding the majority of the market in this region. For instance, according to the Canada Cancer Society report that there were over 6,700 Canadians diagnosed with leukemia, of which around 4,000 were men and about 2,700 were women in 2021. Also, the American Cancer Society documented that approximately 60,650 new cases of leukemia and 20,050 new cases of acute myeloid leukemia (AML) were diagnosed in the United States in 2022. Also, acute myeloid leukemia (AML) made up only about 1% of all cancers. Furthermore, Abbott Laboratories, Thermofisher Scientific, and Illumina are among the key market players holding the majority of market share based in the North American region ensuring the dominance of the region over the global market.
Competitive Landscape
The major global players include F. Hoffman-La Roche Ltd., Abbott Laboratories, Qiagen N.V., Thermo Fisher Scientific, Inc., Illumina, Inc., Bio-Rad Laboratories, Inc., ICON PLC, Archerdx, Inc., Invivoscribe, Inc., and Adaptive Biotechnologies.
COVID-19 Impact Analysis
By Type of Product & Service
• Instruments
• Reagents & Consumables
• Services
By Technology
• PCR (Polymerase Chain Reaction)
• IHC (immunohistochemical)
• NGS (Next-Generation Sequencing)
• Cytogenetics
• Others
By Cancer Type
• Leukemia
o Acute Myeloid Leukemia
o Acute Lymphocytic Leukemia
o Others
• Lymphoma
• Multiple myelomas
• Others
By End-user
• Clinical Laboratories
• Hospitals
• Academic & Research Institutes
• Others
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o UK
o France
o Italy
o Russia
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Key Developments
• In 2022, the US FDA granted approval to F. Hoffmann-La Roche Ltd. (Switzerland) for its cobras EZH2 mutation test as a companion diagnostic for patients with follicular lymphoma.
• In 2020, F. Hoffmann-La Roche Ltd. (Switzerland) and Illumina Inc. (US) formed a 15-year non-exclusive collaboration with Illumina to extend the adoption of NGS-based testing in oncology.
• In 2021, QIAGEN N.V. (Germany) and Denovo Biopharma LLC (US) formed a partnership to design a blood-based companion diagnostic (CDx) test for the treatment of diffuse large B-cell lymphoma (DLBCL), one of the most typical lymphoid cancers.
Why Purchase the Report?
• To visualize the global Hemato Oncology Testing- market segmentation based on product, application and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of Hemato Oncology Testing market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global Hemato Oncology Testing market report would provide approximately 69 tables, 71 figures and 195 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Type of Products & Services
3.2. Snippet by Technology
3.3. Snippet by Type of cancer
3.4. Snippet by End-user
3.5. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Technological Advancements In Drug Diagnosis And Services
4.1.1.2. Increasing Prevalence of Hematologic Cancer Globally
4.1.1.3. XX
4.1.2. Restraints
4.1.2.1. Unfavorable And Uncertain Reimbursement Scenario
4.1.2.2. XX
4.1.3. Opportunity
4.1.3.1. XX
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Forces Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Before COVID-19 Scenario
6.1.2. Present COVID-19 Scenario
6.1.3. Post COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Type of Product & Service
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type of Product & Service
7.1.2. Market Attractiveness Index, By Type of Product & Service
7.2. Instruments
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Reagents & Consumables
7.4. Services
8. By Technology
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
8.1.2. Market Attractiveness Index, By Technology
8.2. PCR (Polymerase Chain Reaction) *
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. IHC (immunohistochemical)
8.4. NGS (Next-Generation Sequencing)
8.5. Cytogenetics
8.6. Others
9. By Cancer Type
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
9.1.2. Market Attractiveness Index, By Cancer Type
9.2. Leukemia*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.2.3. Acute Myeloid Leukemia
9.2.4. Acute Lymphocytic Leukemia
9.2.5. Others
9.3. Lymphoma
9.4. Multiple myelomas
9.5. Others
10. By End-user
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
10.1.2. Market Attractiveness Index, By End-user
10.2. Clinical Laboratories*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Hospitals
10.4. Academic & Research Institutes
10.5. Others
11. By Region
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type of Product & Service
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Caner Type
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.7.1. U.S.
11.2.7.2. Canada
11.2.7.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Caner Type
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.6.1. Germany
11.3.6.2. UK
11.3.6.3. France
11.3.6.4. Italy
11.3.6.5. Russia
11.3.6.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Caner Type
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.6.1. Brazil
11.4.6.2. Argentina
11.4.6.3. Rest of South America
11.5. Asia-Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Caner Type
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.6.1. China
11.5.6.2. India
11.5.6.3. Japan
11.5.6.4. Australia
11.5.6.5. Rest of Asia-Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Caner Type
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
12. Competitive Landscape
12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis
13. Company Profiles
13.1. F. Hoffman-La Roche Ltd.*
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Financial Overview
13.1.4. Key Developments
13.2. Abbott Laboratories
13.3. Qiagen N.V.
13.4. Thermo Fisher Scientific, Inc.
13.5. Illumina, Inc.
13.6. Bio-Rad Laboratories, Inc.
13.7. ICON PLC
13.8. Archerdx, Inc.
13.9. Invivoscribe, Inc.
13.10. Adaptive Biotechnologies
LIST NOT EXHAUSTIVE
14. Appendix
14.1. About Us and Services
14.2. Contact Us

언급된 주요 기업들

F. Hoffman-La Roche Ltd., 4.	Key Developments, Abbott Laboratories, Qiagen N.V., Thermo Fisher Scientific, Inc., Illumina, Inc., Bio-Rad Laboratories, Inc., ICON PLC, Archerdx, Inc., Invivoscribe, Inc., Adaptive Biotechnologies

표 목록 (Tables)

List of Tables

Table 1 Global Hemato Oncology Testing Market Value, By Type of Product & Service, 2022, 2026 & 2030 (US$ Million)

Table 2 Global Hemato Oncology Testing Market Value, By Technology, 2022, 2026 & 2030 (US$ Million)

Table 3 Global Hemato Oncology Testing Market Value, By Cancer Type, 2022, 2026 & 2030 (US$ Million)

Table 4 Global Hemato Oncology Testing Market Value, By End-user, 2022, 2026 & 2030 (US$ Million)

Table 5 Global Hemato Oncology Testing Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 6 Global Hemato Oncology Testing Market Value, By Type of Product & Service, 2022, 2026 & 2030 (US$ Million)

Table 7 Global Hemato Oncology Testing Market Value, By Type of Product & Service, 2021-2030 (US$ Million)

Table 8 Global Hemato Oncology Testing Market Value, By Technology, 2022, 2026 & 2030 (US$ Million)

Table 9 Global Hemato Oncology Testing Market Value, By Technology, 2021-2030 (US$ Million)

Table 10 Global Hemato Oncology Testing Market Value, By Cancer Type, 2022, 2026 & 2030 (US$ Million)

Table 11 Global Hemato Oncology Testing Market Value, By Cancer Type, 2021-2030 (US$ Million)

Table 12 Global Hemato Oncology Testing Market Value, By End-user, 2022, 2026 & 2030 (US$ Million)

Table 13 Global Hemato Oncology Testing Market Value, By End-user, 2021-2030 (US$ Million)

Table 14 Global Hemato Oncology Testing Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 15 Global Hemato Oncology Testing Market Value, By Region, 2021-2030 (US$ Million)

Table 16 North America Hemato Oncology Testing Market Value, By Type of Product & Service, 2021-2030 (US$ Million)

Table 17 North America Hemato Oncology Testing Market Value, By Technology, 2021-2030 (US$ Million)

Table 18 North America Hemato Oncology Testing Market Value, By Cancer Type, 2021-2030 (US$ Million)

Table 19 North America Hemato Oncology Testing Market Value, By End-user, 2021-2030 (US$ Million)

Table 20 North America Hemato Oncology Testing Market Value, By Country, 2021-2030 (US$ Million)

Table 21 South America Hemato Oncology Testing Market Value, By Type of Product & Service, 2021-2030 (US$ Million)

Table 22 South America Hemato Oncology Testing Market Value, By Technology, 2021-2030 (US$ Million)

Table 23 South America Hemato Oncology Testing Market Value, By Cancer Type, 2021-2030 (US$ Million)

Table 24 South America Hemato Oncology Testing Market Value, By End-user, 2021-2030 (US$ Million)

Table 25 South America Hemato Oncology Testing Market Value, By Country, 2021-2030 (US$ Million)

Table 26 Europe Hemato Oncology Testing Market Value, By Type of Product & Service, 2021-2030 (US$ Million)

Table 27 Europe Hemato Oncology Testing Market Value, By Technology, 2021-2030 (US$ Million)

Table 28 Europe Hemato Oncology Testing Market Value, By Cancer Type, 2021-2030 (US$ Million)

Table 29 Europe Hemato Oncology Testing Market Value, By End-user, 2021-2030 (US$ Million)

Table 30 Europe Hemato Oncology Testing Market Value, By Country, 2021-2030 (US$ Million)

Table 31 Asia-Pacific Hemato Oncology Testing Market Value, By Type of Product & Service, 2021-2030 (US$ Million)

Table 32 Asia-Pacific Hemato Oncology Testing Market Value, By Technology, 2021-2030 (US$ Million)

Table 33 Asia-Pacific Hemato Oncology Testing Market Value, By Cancer Type, 2021-2030 (US$ Million)

Table 34 Asia-Pacific Hemato Oncology Testing Market Value, By End-user, 2021-2030 (US$ Million)

Table 35 Asia-Pacific Hemato Oncology Testing Market Value, By Country, 2021-2030 (US$ Million)

Table 36 Middle East & Africa Hemato Oncology Testing Market Value, By Type of Product & Service, 2021-2030 (US$ Million)

Table 37 Middle East & Africa Hemato Oncology Testing Market Value, By Technology, 2021-2030 (US$ Million)

Table 38 Middle East & Africa Hemato Oncology Testing Market Value, By Cancer Type, 2021-2030 (US$ Million)

Table 39 Middle East & Africa Hemato Oncology Testing Market Value, By End-user, 2021-2030 (US$ Million)

Table 40 F. Hoffman-La Roche Ltd.: Overview

Table 41 F. Hoffman-La Roche Ltd.: Product Portfolio

Table 42 F. Hoffman-La Roche Ltd.: Key Developments

Table 43 Abbott Laboratories: Overview

Table 44 Abbott Laboratories: Product Portfolio

Table 45 Abbott Laboratories: Key Developments

Table 46 Qiagen N.V.: Overview

Table 47 Qiagen N.V.: Product Portfolio

Table 48 Qiagen N.V.: Key Developments

Table 49 Thermo Fisher Scientific, Inc.: Overview

Table 50 Thermo Fisher Scientific, Inc.: Product Portfolio

Table 51 Thermo Fisher Scientific, Inc.: Key Developments

Table 52 Illumina, Inc.: Overview

Table 53 Illumina, Inc.: Product Portfolio

Table 54 Illumina, Inc.: Key Developments

Table 55 Bio-Rad Laboratories, Inc.: Overview

Table 56 Bio-Rad Laboratories, Inc.: Product Portfolio

Table 57 Bio-Rad Laboratories, Inc.: Key Developments

Table 58 ICON PLC: Overview

Table 59 ICON PLC: Product Portfolio

Table 60 ICON PLC: Key Developments

Table 61 Archerdx, Inc.: Overview

Table 62 Archerdx, Inc.: Product Portfolio

Table 63 Archerdx, Inc.: Key Developments

Table 64 Invivoscribe, Inc.: Overview

Table 65 Invivoscribe, Inc.: Product Portfolio

Table 66 Invivoscribe, Inc.: Key Developments

Table 67 Adaptive Biotechnologies: Overview

Table 68 Adaptive Biotechnologies: Product Portfolio

Table 69 Adaptive Biotechnologies: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Hemato Oncology Testing Market Value, 2021-2030 (US$ Million)

Figure 2 Global Hemato Oncology Testing Market Share, By Type of Product & Service, 2022 & 2030 (%)

Figure 3 Global Hemato Oncology Testing Market Share, By Technology, 2022 & 2030 (%)

Figure 4 Global Hemato Oncology Testing Market Share, By Cancer Type, 2022 & 2030 (%)

Figure 5 Global Hemato Oncology Testing Market Share, By End-user, 2022 & 2030 (%)

Figure 6 Global Hemato Oncology Testing Market Share, By Region, 2022 & 2030 (%)

Figure 7 Global Hemato Oncology Testing Market Y-o-Y Growth, By Type of Product & Service, 2022-2030 (%)

Figure 8 Instruments Hemato Oncology Testing Market Value, 2021-2030 (US$ Million)

Figure 9 Reagents & Consumables Hemato Oncology Testing Market Value, 2021-2030 (US$ Million)

Figure 10 Services Hemato Oncology Testing Market Value, 2021-2030 (US$ Million)

Figure 11 Global Hemato Oncology Testing Market Y-o-Y Growth, By Technology, 2022-2030 (%)

Figure 12 PCR (Polymerase Chain Reaction) Technology in Global Hemato Oncology Testing Market Value, 2021-2030 (US$ Million)

Figure 13 IHC (immunohistochemical) Technology in Global Hemato Oncology Testing Market Value, 2021-2030 (US$ Million)

Figure 14 NGS (Next-Generation Sequencing) Technology in Global Hemato Oncology Testing Market Value, 2021-2030 (US$ Million)

Figure 15 Cytogenetics Technology in Global Hemato Oncology Testing Market Value, 2021-2030 (US$ Million)

Figure 16 Others Technology in Global Hemato Oncology Testing Market Value, 2021-2030 (US$ Million)

Figure 17 Global Hemato Oncology Testing Market Y-o-Y Growth, By Cancer Type, 2022-2030 (%)

Figure 18 Leukemia Cancer Type in Global Hemato Oncology Testing Market Value, 2021-2030 (US$ Million)

Figure 19 Lymphoma Cancer Type in Global Hemato Oncology Testing Market Value, 2021-2030 (US$ Million)

Figure 20 Multiple myelomas Cancer Type in Global Hemato Oncology Testing Market Value, 2021-2030 (US$ Million)

Figure 21 Others Cancer Type in Global Hemato Oncology Testing Market Value, 2021-2030 (US$ Million)

Figure 22 Global Hemato Oncology Testing Market Y-o-Y Growth, By End-user, 2022-2030 (%)

Figure 23 Clinical Laboratories End-user in Global Hemato Oncology Testing Market Value, 2021-2030 (US$ Million)

Figure 24 Hospitals End-user in Global Hemato Oncology Testing Market Value, 2021-2030 (US$ Million)

Figure 25 Academic & Research Institutes End-user in Global Hemato Oncology Testing Market Value, 2021-2030 (US$ Million)

Figure 26 Other End-user in Global Hemato Oncology Testing Market Value, 2021-2030 (US$ Million)

Figure 27 Global Hemato Oncology Testing Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure 28 North America Hemato Oncology Testing Market Value, 2021-2030 (US$ Million)

Figure 29 Asia-Pacific Hemato Oncology Testing Market Value, 2021-2030 (US$ Million)

Figure 30 Europe Hemato Oncology Testing Market Value, 2021-2030 (US$ Million)

Figure 31 South America Hemato Oncology Testing Market Value, 2021-2030 (US$ Million)

Figure 32 Middle East and Africa Hemato Oncology Testing Market Value, 2021-2030 (US$ Million)

Figure 33 North America Hemato Oncology Testing Market Value, 2021-2030 (US$ Million)

Figure 34 North America Hemato Oncology Testing Market Share, By Type of Product & Service, 2022 & 2030 (%)

Figure 35 North America Hemato Oncology Testing Market Share, By Technology, 2022 & 2030 (%)

Figure 36 North America Hemato Oncology Testing Market Share, By Cancer Type, 2022 & 2030 (%)

Figure 37 North America Hemato Oncology Testing Market Share, By End-user, 2022 & 2030 (%)

Figure 38 North America Hemato Oncology Testing Market Share, By Country, 2022 & 2030 (%)

Figure 39 South America Hemato Oncology Testing Market Value, 2021-2030 (US$ Million)

Figure 40 South America Hemato Oncology Testing Market Share, By Type of Product & Service, 2022 & 2030 (%)

Figure 41 South America Hemato Oncology Testing Market Share, By Technology, 2022 & 2030 (%)

Figure 42 South America Hemato Oncology Testing Market Share, By Cancer Type, 2022 & 2030 (%)

Figure 43 South America Hemato Oncology Testing Market Share, By End-user, 2022 & 2030 (%)

Figure 44 South America Hemato Oncology Testing Market Share, By Country, 2022 & 2030 (%)

Figure 45 Europe Hemato Oncology Testing Market Value, 2021-2030 (US$ Million)

Figure 46 Europe Hemato Oncology Testing Market Share, By Type of Product & Service, 2022 & 2030 (%)

Figure 47 Europe Hemato Oncology Testing Market Share, By Technology, 2022 & 2030 (%)

Figure 48 Europe Hemato Oncology Testing Market Share, By Cancer Type, 2022 & 2030 (%)

Figure 49 Europe Hemato Oncology Testing Market Share, By End-user, 2022 & 2030 (%)

Figure 50 Europe Hemato Oncology Testing Market Share, By Country, 2022 & 2030 (%)

Figure 51 Asia-Pacific Hemato Oncology Testing Market Value, 2021-2030 (US$ Million)

Figure 52 Asia-Pacific Hemato Oncology Testing Market Share, By Type of Product & Service, 2022 & 2030 (%)

Figure 53 Asia-Pacific Hemato Oncology Testing Market Share, By Technology, 2022 & 2030 (%)

Figure 54 Asia-Pacific Hemato Oncology Testing Market Share, By Cancer Type, 2022 & 2030 (%)

Figure 55 Asia-Pacific Hemato Oncology Testing Market Share, By End-user, 2022 & 2030 (%)

Figure 56 Asia-Pacific Hemato Oncology Testing Market Share, By Country, 2022 & 2030 (%)

Figure 57 Middle East & Africa Hemato Oncology Testing Market Value, 2021-2030 (US$ Million)

Figure 58 Middle East & Africa Hemato Oncology Testing Market Share, By Type of Product & Service, 2022 & 2030 (%)

Figure 59 Middle East & Africa Hemato Oncology Testing Market Share, By Technology, 2022 & 2030 (%)

Figure 60 Middle East & Africa Hemato Oncology Testing Market Share, By Cancer Type, 2022 & 2030 (%)

Figure 61 Middle East & Africa Hemato Oncology Testing Market Share, By End-user, 2022 & 2030 (%)

Figure 62 F. Hoffman-La Roche Ltd.: Financials

Figure 63 Abbott Laboratories: Financials

Figure 64 Qiagen N.V.: Financials

Figure 65 Thermo Fisher Scientific, Inc.: Financials

Figure 66 Illumina, Inc.: Financials

Figure 67 Bio-Rad Laboratories, Inc.: Financials

Figure 68 ICON PLC: Financials

Figure 69 Archerdx, Inc.: Financials

Figure 70 Invivoscribe, Inc.: Financials

Figure 71 Adaptive Biotechnologies: Financials

글로벌 혈액종양학 검사 시장 – 2023-2030

Global Hemato Oncology Testing Market - 2023-2030